News >

LILAC Safety Analysis Confirms Similarity of Trastuzumab Biosimilar ABP 980

Caroline Seymour
Published: Friday, Aug 16, 2019

Hans-Christian Kolberg, MD, head of the Department of Obstetrics and Gynecology, Breast Cancer Center, and Gynecologic Cancer Center at Marienhospital Bottrop

Hans-Christian Kolberg, MD

Prespecified analyses from the phase III LILAC trial confirmed the tolerability and clinical similarity in cardiac safety between ABP 980 (Kanjinti; trastuzumab-anns), a trastuzumab (Herceptin) biosimilar, and reference trastuzumab. These types of analyses are critical in enhancing provider confidence, said Hans-Christian Kolberg, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Addressing Uncertainties in Oncology BiosimilarsApr 30, 20201.5
Community Practice Connections™: Show Me the Data™: Leveraging the Evidence to Optimize Applications of Biosimilars in CancerAug 30, 20201.5
Publication Bottom Border
Border Publication
x